Tag: multiple sclerosis
-
Multiple Sclerosis (MS) Drugs Gilenya and Ocrevus Associated With a Higher Likelihood of Melanoma Skin Cancer
Other MS Treatments Such as Lemtrada and Mayzent May Have an Increased Risk of Basal Cell Carcinoma and Squamous Cell Carcinoma (Posted by Tom Lamb at Drug Injury Watch) An analysis of skin cancers reported…
-
Lemtrada ANCA-Associated Systemic Vasculitis Case Report Presented In Recent Medical Journal Article
Lemtrada Side Effects Range From Drug-Induced Autoimmune Complications To Cardiovascular Reactions (Posted by Tom Lamb at DrugInjuryWatch.com) Medical researchers in Switzerland recently presented the case of a 26-year-old man who developed life-threatening…
-
New MS Drug Ocrevus Gets Possible Bad News About Side Effects Soon After Good News About Sales Projections
Ocrevus – Progressive Multifocal Leukoencephalopathy (PML) Reported As Possible Side Effect In Germany, Says Drug Maker Roche (Posted by Tom Lamb at DrugInjuryWatch.com) In March 2017 the FDA approved Ocrevus (ocrelizumab injection)…
-
Multiple Sclerosis Drug Tecfidera: FDA Mandates January 2017 Label Change Which Adds Warnings About Liver Injury Cases
Besides Hepatotoxicity, Progressive Multifocal Leukoencephalopathy, Renal Toxicity, And Other Safety Issues Have Surfaced Since Clinical Trials (Posted by Tom Lamb at DrugInjuryWatch.com) Tecfidera (dimethyl fumarate) was approved by the FDA in 2013…
-
A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice
Biogen Idec First Added Information About Tecfidera Being Assoicated With PML Brain Infection Back In December 2014, After An FDA Drug Safety Communication Was Issued (Posted by Tom Lamb at DrugInjuryWatch.com) Tecfidera…
-
Potential Link Between MS Drug Gilenya And Cancers, Neoplasms, Or Tumors According To Health Canada
This September 2015 Drug Safety Alert Is Based Primarily On Reports Of Skin Cancer And Lymphoma Blood Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) Health Canada recently conducted a review of safety…
-
Multiple Sclerosis (MS) Medication Gilenya: Timeline Of Actions Taken In US, Canada, And Europe
Increasing Safety Concerns About Novartis Drug Gilenya Are Primarily Cardiovascular Side Effects And Unexplained Death (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2012 Health Canada issued the latest drug safety alert concerning Gilenya…